Medtronic received FDA clearance for its NC Euphora Noncompliant Balloon Dilatation Catheter and the company is showing off the new device at the ongoing Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.
The device is used to push drug eluting stents against vessel walls in order to achieve a high level of contact, improving drug transfer and helping to prevent stent narrowing, restenosis, and the formation of blood clots.
Device features according to Medtronic’s announcement:
- Superior Deliverability: PowerTrac(TM) technology provides superior deliverability through challenging lesions and requires less force to track through tortuous anatomy.
- Excellent Re-cross: An optimized tapered tip design and low lesion entry profile improves flexibility and allows for reliable stent re-cross when traversing long, challenging lesions so that the balloon does not catch on a strut when passing through a deployed stent.
- Durability: Strong and flexible proprietary balloon material provides high pressure capability, which enables NC Euphora to expand consistently within the stent area at a Rated Burst Pressure (the maximum pressure that the balloon can be repeatedly inflated in a safe manner) of up to 20 atmospheres without bursting.
- Low Growth Profile: Significantly low radial growth to reduce unwanted vessel expansion and low longitudinal growth beyond the stent length to minimize damage to the surrounding healthy artery.
- Enhanced Packaging: Environmentally friendly packaging and a reduced box size that has a smaller footprint on congested shelves and a broad size range labeled clearly and intuitively.
Press release: Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance…
